Using expanded natural killer cells after haploidentical stem cell transplantation for blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of expanded natural killer (NK) cells following haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The approach aims to enhance the immune response against tumor cells by administering NK cells derived from the patient's haploidentical donor after transplantation. The primary focus is to assess the safety and feasibility of this method, as well as the activity of the NK cells in combating relapse of AML/MDS. Participants will be monitored for their response and any potential side effects associated with the treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patient:

* \>18 years of age
* No HLA-matched related or unrelated donor available
* AML or MDS-EB with indication for a haplo-HSCT according to the guidelines of the University Hospital Basel Stem Cell Transplant Team
* Judged by the transplant physicians to have adequate organ function and no contraindications to haplo-HSCT
* Available related haploidentical donor
* Written informed consent

Donor:

* \>18 years old, haploidentical parent, sibling or other relative
* Donor suitable for cell donation and apheresis according to standard criteria
* Written informed consent

Exclusion Criteria:

Patient:

* APL diagnosis
* Presence of relevant (mean fluorescence intensity \>2000) donor-specific anti-HLA antibodies
* Pregnancy
* Necessity of immunosuppression apart from GvHD prophylaxis

Exclusion Criteria:

Donor:

• Pregnancy

Where it's running

• University Hospital Basel
  Basel, Switzerland Recruiting

Study contacts

• Principal investigator: Jakob Passweg, Prof. MD — University Hospital Basel, Basel Switzerland
• Study coordinator: Matyas Ecsedi, MD-PhD
• Email: matyas.ecsedi@usb.ch
• Phone: +41612652525

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• CD33-armed immune cell treatment for adults with MRD-positive AML or MDS

  This treatment will try giving adults with MRD-positive AML or MDS infusions of their own T cells coated with a CD33-directed bispecific antibody together with standard hypomethylating therapy (and possibly venetoclax) to see if it is safe and lowers residual disease.

  Recruiting Phase 1 University of Virginia · Charlottesville, Virginia · NCT07270978

• Venetoclax-enhanced BUCY versus standard BUCY conditioning for high‑risk AML and MDS before allogeneic stem cell transplant

  This will test whether adding venetoclax to BUCY conditioning before allogeneic stem cell transplant helps patients aged 12–60 with high‑risk AML or MDS stay in remission longer.

  Recruiting First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07183878

• Blood transfusions at home

  This pilot tests whether giving required blood transfusions at home works well and is acceptable for adults with transfusion-dependent blood cancers or bone marrow failure who receive care at SKCCC.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07121140

• Adding decitabine and venetoclax to fludarabine/melphalan reduced‑intensity transplant for myeloid cancers

  This study tests whether giving decitabine and venetoclax around a reduced‑intensity allogeneic transplant is safe for adults with high‑risk acute myeloid leukemia or myelodysplastic syndromes.

  Recruiting Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT07044544

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.